Characteristics of patients and grafts
| Characteristic . | BMT or PBSCT recipient . | CBT recipient . | P* . |
|---|---|---|---|
| Recipients, n | 71 | 100 | — |
| Age, y | .83 | ||
| Median | 40 | 38 | |
| Range | 16-58 | 16-55 | |
| Weight, kg | .01 | ||
| Median | 59 | 55 | |
| Range | 35-85 | 36-76 | |
| Sex of donor and recipient, no. (%) | .69 | ||
| Male/male | 26 (37) | 29 (29) | |
| Female/female | 15 (21) | 20 (20) | |
| Female/male | 16 (23) | 27 (27) | |
| Male/female | 14 (20) | 24 (24) | |
| CMV serologic status, no. (%) | .37 | ||
| Negative | 6 (9) | 13 (13) | |
| Positive | 64 (91) | 87 (87) | |
| Diagnosis, no. (%) | .10 | ||
| AML | |||
| CR1, CR2 | 8 (11) | 26 (26) | |
| Advanced | 23 (32) | 31 (31) | |
| ALL | |||
| CR1, CR2 | 7 (10) | 9 (9) | |
| Advanced | 10 (14) | 11 (11) | |
| CML | |||
| CP | 7 (10) | 1 (1)† | |
| Advanced | 4 (6) | 5 (5) | |
| MDS | |||
| RA | 4 (6) | 3 (3) | |
| Advanced | 1 (1) | 8 (8) | |
| ML | |||
| CR1, CR2 | 1 (1) | 5 (5)† | |
| Advanced | 6 (9) | 2 (2) | |
| Duration from diagnosis to transplantation, mo | .30 | ||
| Median | 15 | 17.5 | |
| Range | 2-177 | 2-223 | |
| Conditioning, no. (%) | <.01 | ||
| TBI + Ara-C/G-CSF | 31 (44) | 0 | |
| TBI + Ara-C/G-CSF + CY | 14 (20) | 68 (68) | |
| TBI + CY | 10 (14) | 13 (13) | |
| TBI + other combination‡ | 16 (23) | 19 (19) | |
| GVHD prophylaxis, no. (%) | .39 | ||
| CsA | 2 (3) | 4 (4) | |
| CsA + sMTX | 67 (94) | 96 (96) | |
| FK506 + sMTX | 1 (1) | 0 | |
| CsA + MMF | 1 (1) | 0 | |
| G-CSF administration during first 7 d, no. (%) | <.01 | ||
| Yes | 60 (85) | 100 (100) | |
| No | 11 (15) | 0 | |
| Year of transplantation, no. (%) | <.01 | ||
| 1997 to 2000 | 50 (70) | 21 (21) | |
| 2001 to 2005 | 21 (30) | 79 (79) | |
| No. of leukocytes for transplantation, ×107/kg | <.01 | ||
| Median | 33.0 | 2.43 | |
| Range | 6.6-50 | 1.1-5.29 | |
| No. of HLA-A, B, and DRB1 mismatches, no. (%) | <.01 | ||
| 0 | 54 (76) | 0 (0) | |
| 1 | 11 (15) | 16 (16)§ | |
| 2 | 6 (8) | 54 (54)§ | |
| 3 | 0 | 28 (28)§ | |
| 4 | 0 | 2 (2)§ | |
| Extent of ABO match, no. (%) | <.01 | ||
| Match | 39 (55) | 29 (29) | |
| Minor mismatch | 15 (21) | 31 (31) | |
| Major mismatch | 17 (24) | 40 (40) |
| Characteristic . | BMT or PBSCT recipient . | CBT recipient . | P* . |
|---|---|---|---|
| Recipients, n | 71 | 100 | — |
| Age, y | .83 | ||
| Median | 40 | 38 | |
| Range | 16-58 | 16-55 | |
| Weight, kg | .01 | ||
| Median | 59 | 55 | |
| Range | 35-85 | 36-76 | |
| Sex of donor and recipient, no. (%) | .69 | ||
| Male/male | 26 (37) | 29 (29) | |
| Female/female | 15 (21) | 20 (20) | |
| Female/male | 16 (23) | 27 (27) | |
| Male/female | 14 (20) | 24 (24) | |
| CMV serologic status, no. (%) | .37 | ||
| Negative | 6 (9) | 13 (13) | |
| Positive | 64 (91) | 87 (87) | |
| Diagnosis, no. (%) | .10 | ||
| AML | |||
| CR1, CR2 | 8 (11) | 26 (26) | |
| Advanced | 23 (32) | 31 (31) | |
| ALL | |||
| CR1, CR2 | 7 (10) | 9 (9) | |
| Advanced | 10 (14) | 11 (11) | |
| CML | |||
| CP | 7 (10) | 1 (1)† | |
| Advanced | 4 (6) | 5 (5) | |
| MDS | |||
| RA | 4 (6) | 3 (3) | |
| Advanced | 1 (1) | 8 (8) | |
| ML | |||
| CR1, CR2 | 1 (1) | 5 (5)† | |
| Advanced | 6 (9) | 2 (2) | |
| Duration from diagnosis to transplantation, mo | .30 | ||
| Median | 15 | 17.5 | |
| Range | 2-177 | 2-223 | |
| Conditioning, no. (%) | <.01 | ||
| TBI + Ara-C/G-CSF | 31 (44) | 0 | |
| TBI + Ara-C/G-CSF + CY | 14 (20) | 68 (68) | |
| TBI + CY | 10 (14) | 13 (13) | |
| TBI + other combination‡ | 16 (23) | 19 (19) | |
| GVHD prophylaxis, no. (%) | .39 | ||
| CsA | 2 (3) | 4 (4) | |
| CsA + sMTX | 67 (94) | 96 (96) | |
| FK506 + sMTX | 1 (1) | 0 | |
| CsA + MMF | 1 (1) | 0 | |
| G-CSF administration during first 7 d, no. (%) | <.01 | ||
| Yes | 60 (85) | 100 (100) | |
| No | 11 (15) | 0 | |
| Year of transplantation, no. (%) | <.01 | ||
| 1997 to 2000 | 50 (70) | 21 (21) | |
| 2001 to 2005 | 21 (30) | 79 (79) | |
| No. of leukocytes for transplantation, ×107/kg | <.01 | ||
| Median | 33.0 | 2.43 | |
| Range | 6.6-50 | 1.1-5.29 | |
| No. of HLA-A, B, and DRB1 mismatches, no. (%) | <.01 | ||
| 0 | 54 (76) | 0 (0) | |
| 1 | 11 (15) | 16 (16)§ | |
| 2 | 6 (8) | 54 (54)§ | |
| 3 | 0 | 28 (28)§ | |
| 4 | 0 | 2 (2)§ | |
| Extent of ABO match, no. (%) | <.01 | ||
| Match | 39 (55) | 29 (29) | |
| Minor mismatch | 15 (21) | 31 (31) | |
| Major mismatch | 17 (24) | 40 (40) |
Italicized P values are ____.
CMV indicates cytomegalovirus; AML, acute myelogenous leukemia; CR1 and CR2, 1st and 2nd complete remission, respectively: advanced, patients in third complete remission, in relapse, in CML beyond chronic phase, or who had high-risk cytogenetics were classified as high risk; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; CP, chronic phase; MDS, myelodysplastic syndrome; RA, refractory anemia; ML, malignant lymphoma; TBI, total body irradiation: Ara-C, cytosine arabinoside; G-CSF, granulocyte colony-stimulating factor; CY, cyclophosphamide; CsA, cyclosporine; sMTX, short-term methotrexate; FK506, tacrolimus; —, not applicable; and MMF, mycophenolate mofetil.
The Chi-square test was used for categoric variables; the Mann-Whitney test was used for continuous variables.
One patient with ALL in chronic phase and non-Hodgkin lymphoma in first complete remission received cord blood for the treatment of both diseases and was categorized as standard risk.
All conditioning regimens included 12 Gy TBI. In BMT/PBSCT recipient group, 15 patients received TBI + etoposide (60 mg/kg). One patient received TBI + G-CSF–combined Ara-C + fludarabine (90 mg/m2). In CBT recipient group, 5 patients received TBI + G-CSF–combined Ara-C + fludarabine (90 mg/m2), 3 patients received TBI + Ara-C + fludarabine (90 mg/m2), 6 patients received TBI + Ara-C + CY, 2 patients received TBI + one drug (etoposide or thiotepa) + CY, and 3 patients received TBI + fludarabine (90 mg/m2) + melphalan (140 mg/m2).
In 16 patients receiving 1-HLA-antigen-mismatched cord blood grafts, 7 had a mismatch antigen in class I and 9 had a mismatch antigen in class II. In 54 patients receiving 2-antigen-mismatched grafts, 14 had mismatched antigens in class I, 37 had mismatched antigens both in classes I and II, and 3 had mismatched antigens in class II. In 28 patients receiving 3-antigen-mismatched grafts, 18 had 2 class I mismatched antigens and a class II mismatched antigen, and 10 had a class I mismatched antigen and 2 class II mismatched antigens.